Bristol-Myers Squibb Co. (BMY)
BCBA
32,060.00
+200.00 (+0.63%)
Closed
Oct 7, 2026
Day's Range
31,940.0032,300.00
52 wk Range
20,180.0036,340.00
Financial Statements - BMY - Bristol-Myers Squibb Co.
Revenue
48.19B▼ 99.9%
Net Income
7.05B▲ 100.1%Net Margin 14.6%
EBITDA
19.94B▼ 99.9%
Free Cash Flow
12.84B▼ 99.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 48.19B | 69.46T | 45B | 46.15B | 46.38B | 42.51B |
| Cost of Goods | 13.93B | 20.08T | 10.69B | 10.13B | 9.94B | 11.77B |
| Gross Profit | 34.25B | 49.37T | 34.31B | 36.02B | 36.44B | 30.74B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 13.72B | 8.46T | 8.19B | 9.10B | 8.53B | 2.17B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -2.50B | -17.71T | 1.41B | -159M | 895M | -7.62B |
| Pre Tax Income | 9.32B | -12.05T | 8.44B | 7.71B | 8.09B | -6.87B |
| Income Tax | 2.27B | 796.79B | 400M | 1.36B | 1.08B | 2.12B |
| Net Income | 7.05B | -12.84T | 8.04B | 6.34B | 7.01B | -8.99B |
| EPS Basic | 3.47 | -4.41 | 3.88 | 2.97 | 3.24849 | -3.99 |
| EPS Diluted | 3.46 | -4.41 | 3.86 | 2.95 | 3.12 | -3.99 |
| Basic Shares Outstanding | 2.03B | 2.91T | 1.95M | 2.01M | 2.03M | 2.13M |
| Diluted Shares Outstanding | 2.03B | 2.91T | 1.95M | 2.01M | 2.03M | 2.13M |
| Ebit | 11.21B | -9.25T | 9.60B | 8.94B | 9.43B | -5.45B |
| Ebitda | 19.94B | 24.68T | 19.33B | 20.57B | 20.37B | 14.28B |
| Net Income Continuous Operations | 7.05B | -12.84T | 8.04B | 6.34B | 7.01B | -8.99B |
| Minority Interests | -2M | -15M | -15M | -18M | -20M | -20M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
